Ozempic vs Wegovy vs Mounjaro: GLP-1 Drugs Compared

Ozempic vs Wegovy vs Mounjaro is one of the most common questions in the GLP-1 category, and most of the confusion dissolves once you know a single fact: these four popular brands come down to just two active ingredients. Ozempic and Wegovy are semaglutide, a GLP-1 receptor agonist from Novo Nordisk. Mounjaro and Zepbound are tirzepatide, a dual GIP/GLP-1 agonist from Eli Lilly. All of them are FDA-approved, once-weekly injectable prescription drugs that require evaluation by a licensed healthcare provider. Within each pair, the brands differ mainly by their FDA-approved use: type 2 diabetes versus chronic weight management.

The Two Active Ingredients Behind the Brands

Four brands, two molecules:

• Semaglutide (Novo Nordisk): sold as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (a daily oral tablet for type 2 diabetes).
• Tirzepatide (Eli Lilly): sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).

Two older GLP-1 drugs round out the picture: Trulicity (dulaglutide, Eli Lilly) for type 2 diabetes, and liraglutide, sold as Victoza for type 2 diabetes and Saxenda for chronic weight management.

This structure is deliberate. A manufacturer runs separate trial programs for separate indications, and the FDA approves each under its own brand. That is why the same molecule can arrive in two different boxes with two different labels — and, frequently, two very different insurance outcomes.

How GLP-1 Drugs Work

GLP-1 receptor agonists like semaglutide mimic the GLP-1 incretin hormone. They prompt the pancreas to release insulin when blood sugar rises, suppress glucagon, slow stomach emptying, and reduce appetite.

Tirzepatide does all of that and also activates the GIP receptor, a second gut-hormone pathway involved in insulin response and energy handling — which is why it is described as a dual agonist rather than a single GLP-1 agonist. Clinical trials have generally shown strong results for tirzepatide across its studied populations. Learn more in semaglutide vs tirzepatide, or on the semaglutide and tirzepatide reference pages.

Ozempic vs Wegovy vs Mounjaro: Brand-by-Brand Snapshot

• Ozempic (semaglutide): FDA-approved for type 2 diabetes; certain doses carry a cardiovascular risk-reduction indication. Once-weekly injection.
• Wegovy (semaglutide): FDA-approved for chronic weight management; some uses include cardiovascular risk reduction. Once-weekly injection.
• Rybelsus (semaglutide): FDA-approved for type 2 diabetes; a daily oral tablet with strict timing instructions.
• Mounjaro (tirzepatide): FDA-approved for type 2 diabetes. Once-weekly injection.
• Zepbound (tirzepatide): FDA-approved for chronic weight management. Once-weekly injection.
• Trulicity (dulaglutide): FDA-approved for type 2 diabetes; cardiovascular indication for certain patients. Once-weekly injection.

The pattern to internalize: within a molecule, the brand tells you the approved indication, not the strength or the chemistry. Ozempic and Wegovy are the same drug for different labels — see Ozempic vs Wegovy. So are Mounjaro and Zepbound. Across molecules, the difference is real pharmacology — see Mounjaro vs Ozempic and Zepbound vs Wegovy.

Effectiveness: What Studies Suggest

Clinical trials have generally shown that tirzepatide can produce greater average weight loss and blood sugar reduction than semaglutide for many people, and both molecules have generally outperformed older GLP-1 options such as dulaglutide and liraglutide in their studied populations.

Two caveats matter. First, "greater on average" is not the same as "right for you." Individual response, tolerance, other health conditions, drug interactions, and access all shape the outcome. Second, cross-trial comparisons are difficult to interpret because populations, doses, titration schedules, and endpoints differ between studies. Only a healthcare provider can weigh this evidence against your circumstances.

Who Is Eligible

Eligibility is a clinical determination, not a self-assessment. Broadly, the diabetes-indicated brands are considered for adults with type 2 diabetes whose blood sugar is not adequately controlled with diet, exercise, and existing therapy. The weight-management brands are considered for adults meeting the body-mass-index thresholds in their labels — either obesity, or overweight plus a weight-related condition such as high blood pressure or obstructive sleep apnea. None of these drugs is approved for type 1 diabetes.

All carry a boxed warning about thyroid C-cell tumors observed in animal studies, and none is recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Clinicians also screen for a history of pancreatitis, gallbladder disease, severe gastrointestinal or motility disorders, kidney impairment, diabetic retinopathy, pregnancy or plans to become pregnant, and interactions with insulin or sulfonylureas, which raise the risk of low blood sugar.

How They Are Taken

Ozempic, Wegovy, Mounjaro, Zepbound, and Trulicity are all once-weekly subcutaneous injections given with a pre-filled pen into the abdomen, thigh, or upper arm, with the site rotated between doses. Rybelsus is a daily oral tablet that must be taken exactly as directed — on an empty stomach with a small sip of water, waiting before eating, drinking, or taking other oral medications — because absorption is sensitive to food and timing.

All are started at a low dose and increased gradually under medical supervision. This titration is standard in the class and exists to limit gastrointestinal side effects. Never adjust your own dose or switch brands on your own, even between two brands of the same molecule. General technique is covered in peptide injections.

What to Expect: Side Effects Across the Class

All of these drugs share a broadly similar side-effect profile, most commonly gastrointestinal:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal discomfort
• Reduced appetite
• Fatigue and injection site reactions

These tend to be most noticeable when starting treatment or increasing the dose, and often ease as the body adjusts. Serious risks including pancreatitis and gallbladder problems have been reported across the class, and severe or persistent abdominal pain warrants prompt medical attention. This is not a complete list — review the full prescribing information and medication guide with your provider or pharmacist. For a broader view, see peptide side effects.

Beyond side effects, expect a course of care rather than a one-time decision: follow-up visits, lab monitoring, and adjustments over months. Weight change is common across the class but is only the approved purpose of some brands.

Cost and Insurance Coverage

This is where identical molecules diverge most sharply. Cost varies widely by insurance plan, pharmacy, region, and year, and we do not publish prices because any number would be wrong for someone's situation.

The structural pattern is consistent: many plans cover diabetes-indicated brands more readily than weight-management brands. Some employer plans exclude weight-management drugs entirely. Prior authorization, documentation of a diagnosis or BMI, and a required trial of other therapies first are all common. Some plans prefer one manufacturer's brand outright, which in practice often determines what a patient ends up taking more than clinical preference does. Manufacturer savings programs exist and change over time; eligibility usually depends on your insurance type and typically excludes government plans.

Practical steps: ask your insurer which brands are on formulary and at what tier; ask your prescriber's office whether they handle prior authorizations; and verify savings program terms directly at the source rather than from third-party summaries. For broader context, see peptide therapy cost.

Which Might Be Right for You? Talk to Your Doctor

The right medication depends on whether your primary goal is blood sugar control or weight management, along with your medical history, other conditions and medications, preference for a pill or an injection, tolerance of side effects, and coverage. Only a licensed healthcare provider can evaluate your situation and prescribe safely. Use this comparison to arrive at your appointment with better questions, not with a conclusion.

Frequently Asked Questions

What is the difference between Ozempic and Mounjaro?

Ozempic is semaglutide, a GLP-1 agonist. Mounjaro is tirzepatide, a dual GIP/GLP-1 agonist. Both are FDA-approved for type 2 diabetes but are different molecules from different manufacturers.

Are Wegovy and Ozempic the same thing?

They are the same drug — semaglutide — approved for different uses: Wegovy for chronic weight management, Ozempic for type 2 diabetes.

Which GLP-1 drug causes the most weight loss?

Studies have generally favored tirzepatide (Zepbound, Mounjaro) for average weight loss, but individual results vary and only a doctor can advise what is right for you.

Is there a GLP-1 pill?

Yes. Rybelsus is oral semaglutide, taken daily, with strict instructions about timing and food.

The Bottom Line

Ozempic, Wegovy, Mounjaro, and Zepbound boil down to two active ingredients — semaglutide and tirzepatide — differing by mechanism (single versus dual agonist) and by FDA-approved use (diabetes versus weight management). They share common gastrointestinal side effects and the same core safety warnings. The brand you end up on is usually decided by your diagnosis and your insurer, in consultation with your prescriber.

Where to Go From Here

• Weight loss peptides hub — the full category overview.
• Semaglutide vs tirzepatide — the science behind single versus dual agonists.
• Are peptides safe? — how to think about safety, approval status, and risk.